TrialInternational journal of cancer2014

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.

Feng-Cai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.